Regenerative biotech company Creative Medical Health said today it is launching a subsidiary biz, AngioStem, to commercialize its cardiovascular assets.
Assets on hand for the newly launched company include a therapy that uses autologous and allogeneic adult stem cells in combination with modulation of oxidative stress to treat heart failure in patients with cardiovascular disease, Creative Medical Health said.
“At Creative Medical Health, our mission is to identify promising technologies, add value by strengthening the science and intellectual property surrounding the technologies, and subsequently spin off new companies with specialized management teams. The development of a business strategy, the successful acquisition of independent funding to implement the strategy, and the recruitment of a management team to lead the strategy have positioned our cardiac stem cell technology to evolve from a promising technology into a functioning corporation,” Creative Medical Health CEO Timothy Warbington said in prepared remarks.
The company’s initial cardiovascular disease treatment patent also includes in-treatment assessment of oxidative stress, which Creative Medical Health said allows doctors the ability to personalize the treatment protocols.
“I look forward to working with the management team of AngioStem to bring stem cell technologies to patients who currently have no treatment options available. The promise of stem cell therapeutics offers the possibility of specifically utilizing cells of the body to accelerate healing. At AngioStem the aim is to utilize stem cells to generate new blood vessels, which may be applicable to conditions ranging from heart failure, to peripheral artery disease, to stroke,” Creative Medical Health founding board member Dr. Amit Patel said in a press release.
“Utilizing the clinical translational expertise of Dr. Amit Patel, our previous company Medistem was successful at taking a stem cell product from bench to bedside, resulting in a successful exit for our investors. We intend to replicate the previous success at AngioStem,” AngioStem CEO Thomas Ichim said in a prepared statement.
Creative Medical Health said ti owns a “portfolio of technologies” that include a patent for using autologous bone marrow stem cells to treat erectile dysfunction, which is currently in clinical trials.
